Ting Liu

ORCID: 0009-0004-0866-8977
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Endometrial and Cervical Cancer Treatments
  • Cancer Mechanisms and Therapy
  • Radiomics and Machine Learning in Medical Imaging
  • Cancer Treatment and Pharmacology
  • Brain Metastases and Treatment
  • Histone Deacetylase Inhibitors Research
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Treatments and Mutations
  • CAR-T cell therapy research
  • Cervical Cancer and HPV Research
  • Colorectal and Anal Carcinomas
  • Colorectal Cancer Treatments and Studies

Hunan Cancer Hospital
2024

Central South University
2024

Zhongshan Hospital
2020

Fudan University
2020

Sun Yat-sen University
2020

The First Affiliated Hospital, Sun Yat-sen University
2020

Immune checkpoint inhibitors (ICI) have been a potential treatment option for patients with cervical cancer in several clinical studies. We investigated the safety and efficacy of cadonilimab, bispecific antibody targeting PD-1 CTLA-4, plus standard therapy first-line R/M CC (recurrent and/or metastatic cancer).

10.1158/1078-0432.ccr-23-3162 article EN cc-by-nc-nd Clinical Cancer Research 2024-02-19

<div>AbstractPurpose:<p>Immune checkpoint inhibitors (ICI) have been a potential treatment option for patients with cervical cancer in several clinical studies. We investigated the safety and efficacy of cadonilimab, bispecific antibody targeting PD-1 CTLA-4, plus standard therapy first-line R/M CC (recurrent and/or metastatic cancer).</p>Patients Methods:<p>Eligible were assigned to 3 cohorts: cohort A-15 (cadonilimab 15 mg/kg every weeks (Q3W) chemotherapy), A-10...

10.1158/1078-0432.c.7181338.v1 preprint EN 2024-04-15

<div>AbstractPurpose:<p>Immune checkpoint inhibitors (ICI) have been a potential treatment option for patients with cervical cancer in several clinical studies. We investigated the safety and efficacy of cadonilimab, bispecific antibody targeting PD-1 CTLA-4, plus standard therapy first-line R/M CC (recurrent and/or metastatic cancer).</p>Patients Methods:<p>Eligible were assigned to 3 cohorts: cohort A-15 (cadonilimab 15 mg/kg every weeks (Q3W) chemotherapy), A-10...

10.1158/1078-0432.c.7181338 preprint EN 2024-04-15
Coming Soon ...